Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 - Seite 3

cancer. Available on demand from September 18 at ESMO.org.

Cetuximab (ERBITUX®) (Presentations: #397O; 402MO; 511P; 960P; 922P)

For the Company's first biology-driven leader ERBITUX, a number of
investigator-sponsored studies (ISS), including in combination with BAVENCIO
(avelumab), continue to demonstrate its steady role across the continuum of care
in metastatic colorectal cancer, and backbone of treatment of squamous cell
carcinoma of the head and neck. Data demonstrating the role of ERBITUX as a
promising combination partner include an oral presentation investigating
avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal
cancer patients as re-challenge strategy: the Phase II CAVE (cetuximab-avelumab)
mCRC study. This will be presented during the Proffered Paper GI - colorectal
session scheduled on September 19, 2:49pm-3:01pm CEST/8:49am-9:01am EDT
(Presentation #397O)

*BAVENCIO is under clinical investigation for the first-line maintenance
treatment of advanced UC and not yet approved in any markets outside of the US.

? Tepotinib is the International Nonproprietary Name (INN) for the MET kinase
inhibitor MSC2156119J. Tepotinib is currently under clinical investigation in
NSCLC and not yet approved in any markets outside of Japan.

? Bintrafusp alfa is currently under clinical investigation and not approved for
any use anywhere in the world.

About BAVENCIO® (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO
has been shown in preclinical models to engage both the adaptive and innate
immune functions. By blocking the interaction of PD-L1 with PD-1 receptors,
BAVENCIO has been shown to release the suppression of the T cell-mediated
antitumor immune response in preclinical models.10-12 In November 2014, Merck
and Pfizer announced a strategic alliance to co-develop and co-commercialize
BAVENCIO.

BAVENCIO Approved Indications

The European Commission has authorized the use of BAVENCIO in combination with
axitinib for the first-line treatment of adult patients with advanced renal cell
carcinoma (RCC). In September 2017, the European Commission granted conditional
marketing authorization for BAVENCIO as a monotherapy for the treatment of adult
patients with metastatic Merkel cell carcinoma (MCC).

In the US, BAVENCIO® (avelumab) is indicated for the maintenance treatment of
patients with locally advanced or metastatic urothelial carcinoma (UC) that has
not progressed with first-line platinum-containing chemotherapy. BAVENCIO is